Table 1.
Patients baseline characteristics.
| Number (%) | |
|---|---|
| Median Age at diagnosis, years old (y/o) | 50.0 |
| Median age at the time of starting vinorelbine (y/o) | 56.0 |
| Molecular subtype | |
| Lumina A | 24 (26.7) |
| Lumina B | |
| HR+, Her-2 - | 19 (21.1) |
| HR+, Her-2 + | 20 (22.2) |
| Her-2 enrich | 14 (15.6) |
| Her-2 positive | 34 (37.7) |
| TNBC | 13 (14.4) |
| Initial stage at diagnosis | |
| I | 11 (12.2) |
| II | 25 (27.8) |
| III | 16 (17.7) |
| IV | 38 (42.2) |
| Metastatic site at vinorelbine | |
| Lung | 45 (50.0) |
| Liver | 28 (31.1) |
| Brain | 8 (7.8) |
| Bone only | 9(10.0) |
| Skin/Soft tissue | 11(12.2) |
| Others | 12 (13.3) |
| Number of metastatic sites | |
| 1 | 42 (46.7) |
| 2 | 22 (24.4) |
| ≥3 | 26 (28.9) |
| Previous treatment for MBC | |
| 0 | 10 (11.1) |
| 1 | 49 (54.4) |
| 2 | 17(18.9) |
| ≥3 | 14(15.6) |
| Response to previous treatment | |
| CR | 1 (1.1) |
| PR | 45 (50.0) |
| SD | 14 (15.6) |
| PD | 26 (28.9) |
| NE | 4 (4.4) |
HR-hormonal receptor; TNBC- triple negative breast cancer; MBC-metastatic breast cancer; CR-complete response; PR-partial response; SD-stable disease; PD-progressive disease; NE-not evaluated.